PF4 for cognitive impairment, a WNT pathway-targeting kinase inhibitor for cancer and more

Innovations captured last week in BioCentury’s Distillery, a curated database of translational academic research from over 25 journals, included a protein therapy for cognitive impairment, a multikinase inhibitor for β-catenin-mutant hepatocellular carcinomas, and agents for Nipah virus and bacterial infections.

Two studies from separate but collaborating groups at University of California San Francisco and  University of Queensland suggested recombinant PF4, a platelet-derived exerkine, could help treat age-related cognitive impairment by interacting with the chemokine receptor CXCR3 and promoting hippocampal neurogenesis...